Fortress Investment Group LLC Takes Position in Astera Labs, Inc. $ALAB

Fortress Investment Group LLC purchased a new position in shares of Astera Labs, Inc. (NASDAQ:ALAB) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 22,500 shares of the company’s stock, valued at approximately $2,034,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. lifted its holdings in shares of Astera Labs by 11.9% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,268 shares of the company’s stock worth $314,000 after purchasing an additional 560 shares in the last quarter. Atria Wealth Solutions Inc. raised its holdings in shares of Astera Labs by 81.1% in the 1st quarter. Atria Wealth Solutions Inc. now owns 4,543 shares of the company’s stock worth $271,000 after acquiring an additional 2,034 shares during the last quarter. Vanguard Group Inc. lifted its position in Astera Labs by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 9,297,476 shares of the company’s stock valued at $554,780,000 after acquiring an additional 85,846 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Astera Labs by 4.4% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 138,300 shares of the company’s stock valued at $8,252,000 after purchasing an additional 5,828 shares during the last quarter. Finally, Deutsche Bank AG increased its holdings in Astera Labs by 2,448.4% during the 1st quarter. Deutsche Bank AG now owns 196,103 shares of the company’s stock worth $11,701,000 after purchasing an additional 188,408 shares in the last quarter. Institutional investors and hedge funds own 60.47% of the company’s stock.

Astera Labs Trading Down 14.3%

Shares of NASDAQ:ALAB opened at $148.85 on Friday. The stock has a market capitalization of $25.14 billion, a P/E ratio of 134.10, a price-to-earnings-growth ratio of 3.24 and a beta of 1.51. The stock’s 50-day moving average price is $166.62 and its 200-day moving average price is $153.22. Astera Labs, Inc. has a 12-month low of $47.13 and a 12-month high of $262.90.

Astera Labs (NASDAQ:ALAB) last issued its earnings results on Tuesday, November 4th. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.10. Astera Labs had a return on equity of 13.48% and a net margin of 27.50%.The company had revenue of $230.58 million during the quarter, compared to analysts’ expectations of $206.42 million. During the same period in the prior year, the business posted $0.23 EPS. Astera Labs’s quarterly revenue was up 103.9% compared to the same quarter last year. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. As a group, research analysts predict that Astera Labs, Inc. will post 0.34 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. BNP Paribas Exane initiated coverage on Astera Labs in a report on Thursday, November 20th. They set an “outperform” rating and a $225.00 price target on the stock. Citigroup restated an “outperform” rating on shares of Astera Labs in a research report on Tuesday. Stifel Nicolaus raised their price target on Astera Labs from $185.00 to $200.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Needham & Company LLC upped their price objective on Astera Labs from $205.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Finally, Morgan Stanley restated an “overweight” rating and issued a $210.00 target price on shares of Astera Labs in a research report on Wednesday, December 3rd. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, Astera Labs currently has a consensus rating of “Moderate Buy” and an average target price of $188.17.

Insider Activity

In other Astera Labs news, CFO Michael Truett Tate sold 11,430 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of $144.69, for a total transaction of $1,653,806.70. Following the completion of the sale, the chief financial officer owned 192,297 shares of the company’s stock, valued at $27,823,452.93. This represents a 5.61% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel Philip Mazzara sold 4,620 shares of the business’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $144.69, for a total transaction of $668,467.80. Following the completion of the transaction, the general counsel owned 147,040 shares in the company, valued at $21,275,217.60. The trade was a 3.05% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 586,936 shares of company stock valued at $89,331,140. Corporate insiders own 12.50% of the company’s stock.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.